Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2002 | 12-2001 | 12-2000 | 12-1999 | 12-1998 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,690 | -12,100 | -27,290 | 720 | -13,150 |
| Depreciation Amortization | 770 | 1,180 | 1,020 | 1,050 | 1,190 |
| Other Working Capital | 1,420 | -2,430 | 300 | -3,760 | 4,840 |
| Other Operating Activity | 5,250 | -90 | 16,940 | -1,880 | -900 |
| Operating Cash Flow | $-8,250 | $-13,440 | $-9,030 | $-3,870 | $-8,020 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -40 | -810 | -1,060 | 190 | -100 |
| Net Acquisitions | 0 | 0 | 0 | 550 | 2,000 |
| Other Investing Activity | -1,150 | -500 | 1,090 | 1,990 | 0 |
| Investing Cash Flow | $-1,190 | $-1,310 | $30 | $2,730 | $1,900 |
| Cash Flows From Financing Activities | |||||
| Dividend Paid | 0 | 0 | 0 | 0 | -10 |
| Other Financing Activity | 12,860 | 14,070 | 10,190 | 8,930 | 1,740 |
| Financing Cash Flow | $12,860 | $14,070 | $10,190 | $8,930 | $1,730 |
| Beginning Cash Position | 11,300 | 11,990 | 10,800 | 3,010 | 7,400 |
| End Cash Position | 14,720 | 11,300 | 11,990 | 10,800 | 3,010 |
| Net Cash Flow | $3,410 | $-680 | $1,190 | $7,780 | $-4,380 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,250 | -13,440 | -9,030 | -3,870 | -8,020 |
| Free Cash Flow | -8,250 | -13,440 | -9,030 | -3,870 | -8,020 |